A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma.
AuthorsWylie, James P
Cowan, Richard A
Radford, John A
Deakin, David P
Harris, Maggie A
Wilkinson, Peter M
AffiliationDepartment of Clinical Oncology, Christie Hospital NHS Trust, Manchester, UK.
MetadataShow full item record
AbstractA retrospective analysis was performed on 66 patients, aged 70 years or older, who received treatment with a weekly doxorubicin-containing regimen (VAPEC-B) for high grade non-Hodgkin's lymphoma (NHL). Two dosing schedules were employed. The choice of regimen was at the discretion of the treating clinician and reflected the performance status of the patient and the predicted tolerance to chemotherapy. Forty-nine patients received a half-dose schedule and 17 the full-dose schedule. Those receiving the half-dose regimen had a lower median performance status and received a lower dose intensity of chemotherapy (45% versus 83%). However, the outcomes of the two groups were similar: complete remission rate 41% versus 47%, and 5-year overall survival 36% versus 23%, for the half- and full-dose groups, respectively. A similar proportion of patients (51% versus 59%) completed each regimen, although there were more delays in treatment delivery experienced in those receiving the full dose. Half-dose VAPEC-B is an effective treatment option for elderly patients with high-grade NHL and has comparable efficacy with other published regimens. The use of such low-dose doxorubicin-containing regimens in elderly patients with high-grade NHL requires further investigation.
CitationA doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma. 2000, 12 (3):153-7 Clin Oncol
- VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
- Authors: Singer JM, Mijovic A, Pettingale KW, Nethersell A, Dobbs HJ, Samaratunga IR, Lakhani A, Mufti GJ
- Issue date: 1995
- Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
- Authors: Sweetenham JW, Mead GM, Whitehouse JM
- Issue date: 1991 Dec
- Weekly VAPEC-B chemotherapy for high grade non-Hodgkin's lymphoma: results of treatment in 184 patients.
- Authors: Radford JA, Whelan JS, Rohatiner AZ, Deakin D, Harris M, Stansfeld AG, Swindell R, Wilkinson PM, James RD, Lister TA
- Issue date: 1994 Feb
- CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group.
- Authors: Cameron DA, White JM, Proctor SJ, Prescott RJ, Leonard RC, Angus B, Cook MK, Dawes PJ, Dawson AA, Evans RG, Galloway MJ, Harris AL, Heppleston A, Horne CH, Krajewski AS, Lennard AL, Lessells AM, Lucraft HH, MacGillivray JB, Mackie MJ, Parker AC, Roberts JT, Taylor PR, Thompson WD
- Issue date: 1997 Jul
- Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
- Authors: Mainwaring PN, Cunningham D, Gregory W, Hoskin P, Hancock B, Norton AJ, MacLennan K, Smith P, Hudson GV, Linch D
- Issue date: 2001 May 15